Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL - Concepedia

Concepedia

Publication | Open Access

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

DOI Full Paper Access

23

Citations

18

References

2024

Year

Gregory W. Roloff, Ibrahim Aldoss, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal Gupta, Timothy E. O’Connor, Nikeshan Jeyakumar, Ibrahim N. Muhsen, Yannis K. Valtis,

Journal of Clinical Oncology

Abstract

Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

References

	Year	Citations

Page 1